Jpmorgan Chase & CO Royalty Pharma PLC Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Royalty Pharma PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,289,418 shares of RPRX stock, worth $32.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,289,418
Previous 7,739,281
83.34%
Holding current value
$32.9 Million
Previous $204 Million
82.13%
% of portfolio
0.0%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding RPRX
# of Institutions
413Shares Held
283MCall Options Held
578KPut Options Held
47.5K-
Morgan Stanley New York, NY41.1MShares$1.05 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$959 Million0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$587 Million0.01% of portfolio
-
Baillie Gifford & CO16.1MShares$411 Million0.35% of portfolio
-
Viking Global Investors LP12.1MShares$309 Million1.32% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $11.2B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...